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A B S T R A C T
Background: Depression and anxiety are highly prevalent and often co-occur. Several studies indicate the po-
tential of disorder-speciﬁc psychological interventions for the prevention of each of these disorders. To treat
comorbidity, transdiagnostic treatment concepts seem to be a promising approach, however, evidence for
transdiagnostic concepts of prevention remains inconclusive. Internet- and mobile-based interventions (IMIs)
may be an eﬀective means to deliver psychological interventions on a large scale for the prevention of common
mental disorders (CMDs) such as depression and anxiety. IMIs have been shown to be eﬀective in treating CMDs,
e.g. in reducing symptoms of depression and anxiety. However, there is a lack of studies examining the eﬃcacy
of interventions reducing the incidence of CMDs. Moreover, the comparative cost-eﬀectiveness of guided versus
unguided IMIs for the prevention of depression and anxiety has not been studied yet. Hence, this study aims at
investigating the (cost-) eﬀectiveness of guided and unguided internet- and mobile-based transdiagnostic in-
dividually tailored indicated prevention of depression and anxiety.
Methods: A multi-country three-armed randomized controlled trial will be conducted to compare a guided and
unguided intervention to treatment as usual (TAU). Both active conditions are based on the same intervention,
ICare Prevent, and diﬀer only with regard to guidance format. Altogether, 954 individuals with subclinical
symptoms of depression (CES-D≥ 16) and anxiety (GAD-7≥ 5) who do not have a full-blown disorder will be
recruited in Germany, Switzerland, Spain and the Netherlands, and randomized to one of three conditions
(guided intervention, unguided intervention, or TAU). The TAU arm will receive access to the training after a 12-
month waiting period. The primary outcome will be time to CMD onset (any depression/anxiety disorder) within
a follow-up period of 12months after baseline. Secondary outcomes will include disorder-speciﬁc symptom
severity (depression/anxiety) assessed by diagnostic raters blinded to intervention condition at post-interven-
tion, self-reports, acceptability, health related quality of life, and psychosocial variables associated with de-
veloping a CMD. Assessments will take place at baseline, mid-intervention (5 weeks into the intervention), post-
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intervention (8 weeks after randomization) and follow-up (6 and 12months after randomization). Data will be
analyzed on an intention-to-treat basis and per protocol. Cost-eﬀectiveness will be evaluated from a public
health and a societal perspective, including both direct and indirect costs.
Discussion: The present study will further enhance the evidence-base for transdiagnostic preventive interven-
tions and provide valuable information about optimal trade-oﬀ between treatment outcome and costs.
Trial registration: German Clinical Trial Registration (DRKS - http://www.drks.de/drks_web/): DRKS00011099.
1. Introduction
Depression and anxiety disorders, due to their high prevalence, high
disease burden, and common comorbidity (Brenes, 2007; Brown and
Barlow, 1992; Kessler et al., 2005; Klein Hofmeijer-Sevink et al., 2012;
Saarni et al., 2007; Wang et al., 2009), have been identiﬁed as two of
the leading causes of disability (Baxter et al., 2014; Global Burden of
Disease Study 2013 et al., 2015) causing an enormous economic burden
through, e.g. reduced workforce participation, occupational impair-
ment, and lost productivity (Berto et al., 2000; Birnbaum et al., 2010;
Greenberg and Birnbaum, 2005; World Health Organization, 2008).
A variety of eﬀective interventions for the treatment of common
mental disorders (CMDs) have been developed over the past decades,
and their eﬃcacy has been demonstrated in a large number of rando-
mized controlled trials (RCTs) (Cuijpers et al., 2008, 2014b; Hofmann
and Smits, 2008).
However, even though eﬀective treatment modalities exist, most
individuals in need of treatment for depression and anxiety remain
untreated. What also adds to the unmet need for treatment, even when
assuming the hypothetical scenario of 100% coverage and compliance
to evidence-based treatments, is that only approximately one third of
the disease burden attributable to MDD and half of the disease burden
attributable to ADs could be averted with current treatments (Andrews
et al., 2004; Chisholm et al., 2004). For this reason, attention is in-
creasingly focusing on prevention of CMDs, by targeting individuals
before the onset of a full syndrome CMD (Emmelkamp et al., 2014).
Emerging evidence indicates the potential of disorder-speciﬁc in-
terventions to prevent the development of MDD (van Zoonen et al.,
2014). However, evidence on the eﬃcacy of interventions aiming to
prevent the onset of anxiety especially long-term, is inconclusive. This
is indicated by a meta-analysis showing that initial short-term eﬀects
diminish over time (Zalta, 2011). Moreover, another general problem is
the low likelihood that health care systems would implement and dis-
seminate unique prevention programs for each single disorder. Also,
MDD and ADs are highly comorbid (Beekman et al., 2000), and risk
factors and subclinical symptoms of depression and the diﬀerent ADs
overlap (de Graaf et al., 2002; Kessler et al., 1994). Transdiagnostic
concepts aiming at preventing the incidence of both conditions si-
multaneously may therefore show much promise (Barlow et al., 2004;
Brown and Barlow, 1992). Transdiagnostic interventions that target a
set of shared risk factors might increase the potential reach and impact
of psychological prevention programs (Titov et al., 2011).
Comorbidities can also be targeted through individual tailoring
which allows participants to receive individualized treatment protocols
based on symptom proﬁles, preference, need, or characteristics
(Andersson and Titov, 2014; Păsărelu et al., 2017). This also means that
participants following a treatment protocol do not all receive the same
standardized treatment.
However, evidence for the potential of transdiagnostic individually
tailored concepts that target the prevention of MDD and ADs in adults,
so far, is scarce. Only very few RCTs have been conducted that eval-
uated the eﬀects of a psychological intervention on the onset of de-
pression and anxiety disorders, and results have been mixed (Austin
et al., 2008; Joling et al., 2012; van't Veer-Tazelaar et al., 2009a). In
one study (van't Veer-Tazelaar et al., 2009a) the eﬀectiveness of an
indicated stepped-care prevention program of depression and anxiety
disorders was evaluated in an at-risk elderly population and found the
incidence rate halved in a 12-month follow-up. However, others (Austin
et al., 2008) found no signiﬁcant diﬀerences between a cognitive be-
havioral group intervention and the wait control group (WCG, in-
formation booklet) when considering the prevention of depression and
anxiety in an at-risk population of pregnant women. Another study
(Joling et al., 2012) testing the eﬀectiveness of family meetings for at-
risk family caregivers of dementia patients, found no superiority in
preventing depression and anxiety disorders. In sum, more research is
needed to investigate the potential of transdiagnostic psychological
interventions for the prevention of MDD and ADs.
The previously mentioned limitations of conventional prevention
programs could be overcome by utilizing internet- and mobile-based
interventions, e.g. IMIs. Main advantages include: (1) accessibility: they
are easily accessible at any time from any location via the internet, (2)
anonymity: participation is anonymous so that stigmatization or self-
disclosure in group settings can be avoided, (3) ﬂexibility: participation
can be completed at any individual speed, and materials can be re-
viewed as often as desired, (4) personalization: the intervention is
adaptable and can be tailored to speciﬁc needs, and (5) treatment
availability: aﬀected individuals can be reached earlier than through
traditional mental health services. Also, (6) scalability: IMIs are easily
scalable, as by applying a small increase of therapeutic resources a
greater proportion of the eligible population can be reached.
IMIs have already been shown to be eﬀective in reducing symptoms
of diverse psychological disorders, such as the treatment of depression
(Ebert et al., 2015a, 2015b; Königbauer et al., 2017), anxiety (Cuijpers
et al., 2009; Mayo-Wilson and Montgomery, 2013; Olthuis et al., 2015),
sleep disorders (Cheng and Dizon, 2012), eating disorders (Dölemeyer
et al., 2013), or alcohol use disorders (Riper et al., 2014).
However, evidence of the eﬀectiveness in preventing the incidence
of CMDs through internet interventions in public health settings is still
scarce; the latest systematic review identiﬁed ten RCTs that evaluated
the eﬀect of an IMI on CMD onset (Ebert et al., 2017a, 2017b). The only
trial on the prevention of general anxiety did not result in signiﬁcant
positive ﬁndings (Christensen et al., 2014). Of the three primary pre-
vention trials aiming to reduce the incidence of a depressive disorder
(Buntrock et al., 2016a; Imamura et al., 2015; Thompson et al., 2015),
only one trial (Buntrock et al., 2016a; Ebert et al., 2016a) used standard
diagnostic procedures, while the other two trials relied only on self-
report questionnaires for onset identiﬁcation. The aforementioned
study by Buntrock, Ebert and colleagues (Buntrock et al., 2014) showed
that internet-based guided self-help for the indicated prevention of
depression (including at-risk individuals) can reduce symptoms of de-
pression in adults with subthreshold depression (Buntrock et al., 2015)
and reduce the risk of MDD onset by 39% within a year (Buntrock et al.,
2016a).
Even though it is often argued that internet-based interventions are
likely to reduce the treatment costs, evidence from RCTs is still scarce
and even completely absent when it comes to IMIs for the transdiag-
nostic prevention of both MDD and ADs. The only trial we are aware of
evaluating cost-eﬀectiveness of internet-based prevention is the trial
from Buntrock and colleagues in which the authors showed that an IMI
for indicated prevention has a high likelihood for cost-eﬀectiveness,
both from a societal and a public health care perspective (Buntrock
et al., 2017). After the development of an intervention, the primary
running costs are directly related to guidance time.
Previous research on guidance intensity and eﬃcacy led to assume
K.K. Weisel et al. Internet Interventions xxx (xxxx) xxx–xxx
2
that internet-based mental health interventions without any kind of
guidance were less eﬀective than interventions including at least some
guidance from a professional (Johansson and Andersson, 2012;
Richards and Richardson, 2012; Spek et al., 2007). One study ex-
amining the role of support in internet-based problem-solving treat-
ment for symptoms of anxiety and/or depression found that partici-
pants who received weekly support improved signiﬁcantly in reducing
depression compared to a WCG while participants with no guidance,
guidance on demand, or guidance without training showed no sig-
niﬁcant improvement (Kleiboer et al., 2015). Results for the reduction
of anxiety were less pronounced but still in favor of the weekly support
condition. This notion is partly supported by a systematic review
(Baumeister et al., 2014), identifying 14 articles fulﬁlling inclusion
criteria, which showed superiority of guided internet-based interven-
tions for mental health related problems in comparison to unguided
treatment. However, the review and recent emerging evidence also
propose that diﬀerences in outcomes between guided and unguided
interventions are smaller than previously assumed, or might even be
non-existent altogether (Dear et al., 2016; Königbauer et al., 2017; Mira
et al., 2017; Olthuis et al., 2015).
A reason unguided IMIs might be preferable even when potentially
less eﬀective is that they could produce larger eﬀects at a population
level with regard to the reduction of disease burden, as many more
individuals could be reached at comparable costs. The evaluation of
(cost-)eﬀectiveness, therefore, remains an open research question and
more studies are needed directly comparing guided and unguided IMIs
for mental health related issues (Boß et al., 2015; Ebert et al., 2014).
Study aims: This study aims at investigating the (cost-)eﬀectiveness
of a guided and unguided transdiagnostic individually tailored IMI for
the prevention of MDD and AD in a clearly deﬁned subclinical sample.
The subclinical sample is deﬁned by including individuals who show
detectable symptoms of depression and anxiety indicated by a score of
≥16 on the Center for Epidemiological Studies Depression Scale (CES-
D) (Hautzinger et al., 2012; Radloﬀ, 1977) or score of ≥5 on the as-
sessment of the Generalized Anxiety Disorder (GAD-7) (Spitzer et al.,
2006), and who do not fulﬁll criteria for a full-blown AD or MDD as
assessed in a diagnostic interview.
Speciﬁc aims include: 1) to evaluate the eﬃcacy of guided and
unguided IMIs to reduce the incidence of full syndrome CMDs com-
pared to TAU, 2) to assess the eﬃcacy of guided and unguided IMIs on
symptom severity and other psychological outcomes when compared to
TAU, 3) to compare the eﬃcacy of guided and unguided IMIs on the
reduction of symptom severity and other secondary continuous out-
comes, 4) to assess the cost-eﬀectiveness of guided and unguided IMIs,
and lastly 5) to assess and compare the acceptability of guided and
unguided IMIs.
2. Materials and methods
2.1. Objectives and hypotheses
We hypothesize 1) that both guided and unguided IMIs are more
eﬀective and cost-eﬀective than TAU (no intervention); 2) guided IMIs
to show higher eﬀectiveness, lower cost-eﬀectiveness but greater ac-
ceptability by the participants than unguided IMIs.
2.2. Participants
We will include individuals who…
- are at minimum 18 years of age, in the Dutch trial site individuals
can participate from the age of 16,
- score ≥16 on the Center for Epidemiological Studies Depression
Scale (CES-D) (Hautzinger et al., 2012; Radloﬀ, 1977) or score ≥5
on the assessment of the Generalized Anxiety Disorder (GAD-7)
(Spitzer et al., 2006),
- have Internet access and a valid email address,
- suﬃcient language skills in the considered program language in
reading and writing,
- and are willing to give informed consent.
We will exclude individuals who…
- are currently on a waiting list for mental health treatment or have
received psychological treatment in the previous 6months for de-
pression and/or anxiety,
- currently fulﬁll the criteria for a full syndrome MDD or AD ac-
cording to the Mini International Neuropsychiatric Interview
Version 5.0 (Mini) (Sheehan et al., 2006),
- fulﬁlled criteria of an MDD or AD in the previous 6months and
showed a main symptom (Dysphoria, Anhedonia) of MDD in the
previous 3 weeks (to exclude individuals currently in remission of
MDD),
- report to have been diagnosed with psychosis, bipolar disorder or
experienced dissociative symptoms in the past,
- or show a high suicidal risk in the MINI during the diagnostic in-
terview.
- Participate in similar studies at the time of inclusion (only in the
Netherlands).
2.2.1. Recruitment
Participants will be recruited in Germany, Switzerland, Austria,
Spain and the Netherlands. They are primarily recruited through co-
operating health care insurances via their webpages as well as through
members' magazines. Moreover, participants will also be recruited
through an internationally organized mental health care risk assess-
ment in university students (caring university project, WHO World
Mental Health international college survey). Participants in the
Netherlands are recruited through the latter, as well as additional re-
cruitment strategies, such as ﬂyers and posters on campus sites. The
study website provides information about the ICare Prevent online
training (icareprevent.com), the general study procedure, and details
on how to sign up for participation. The trial is open to all individuals
fulﬁlling the inclusion criteria and not restricted to the cooperating
health care insurance companies and universities. Recruitment will
begin in February 2017. Interested individuals can sign up for partici-
pation on the ICare Prevent website (icareprevent.com) or associated
webpages, or contact the study administration team via email directly
(training@icareprevent.com) by providing the research team with their
email address and a name which can be a pseudonym if desired.
2.2.2. Assessment of eligibility and randomization
Individuals who apply for study participation will receive an email
with detailed information about the study procedure. Applicants are
asked to complete online screening questionnaires that assess the se-
verity of their depression (CES-D≥ 16) and their anxiety level (GAD-
7≥ 5). The screening also includes questions on demographical in-
formation, assessment of history and current state of mental health, and
past and current treatment history. Once the screening is completed and
participants fulﬁll the inclusion and do not fulﬁll any exclusion criteria,
participants receive detailed study information and a consent form.
Participants in the Netherlands receive and ﬁll-out the consent form
before the screening. They are notiﬁed that they can withdraw from the
intervention and/or study at any time without any negative con-
sequences. They must sign the consent form and send it back via post or
email. Once the signed consent is received, trained interviewers will
conduct the diagnostic interviews, and individuals that fulﬁll the in-
clusion and none of the exclusion criteria will proceed to complete the
baseline questionnaires. As soon as participants have completed all
baseline questionnaires, they enter the study and are randomized to one
of the three study conditions: guided intervention, unguided interven-
tion, or TAU.
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Participants are randomized to either one of the intervention groups
(unguided intervention or guided intervention) or TAU in a 1:1:1 ratio.
Randomization will be stratiﬁed according to trial site (Germany/
Switzerland, Spain, and the Netherlands), and presence of subclinical
symptoms (three strata: S1, subclinical anxiety; S2, subclinical depres-
sion; S3, subclinical anxiety and subclinical depression). A block-ran-
domization algorithm with concealed block length will be used. The
generation algorithm and resulting lists are validated by an in-
dependent biostatistician not otherwise directly involved in the study.
The generation of randomization lists and the randomization of en-
rolled participants will be performed centrally for all countries by the
ICare partner Westfälische-Wilhelms-Universität Münster (Institute of
Biostatistics and Clinical Research, Westfälische-Wilhelms-Universität
Münster, Germany) not directly involved in the recruitment or active
study phase.
During the randomization process, allocation will be concealed from
participants, researchers involved in recruitment and study adminis-
tration, diagnostic assessors and eCoaches. Once randomization has
been completed by the independent researcher, the study administra-
tion is informed about randomization outcome who inform the parti-
cipants about the outcome (only whether they receive immediate or
delayed access to treatment), and participants in the intervention
groups then receive immediate access to the ICare Prevent training. The
participants in the control group will receive the login data required to
complete the training 12months after randomization.
2.3. Study design
This trial will be conducted in compliance with the protocol, the
Declaration of Helsinki, and good clinical practice. The trial is regis-
tered in the German Clinical Trial Registration (http://www.drks.de/
drks_web/,DRKS00011099).
All procedures involved in the study will be consistent with the
generally accepted standards of ethical practice approved by local
ethics committees of each partnering country:
- Friedrich-Alexander University Erlangen-Nuremberg ethics
committee (144_16 B),
- the Ethics Commission of the Canton of Bern (2016–01389),
- the Ethics Committee of the University of Valencia
(H1476878127646),
- and the Medical Ethics Committee of the Vrije Universiteit
Amsterdam (2017.131).
Data security/conﬁdentially will be guaranteed; all relevant EU
legislation and international texts on privacy will be observed and re-
spected. Regarding regulation at international level, starting from the
OECD guidelines including the “Guidelines on the protection of privacy
and transborder ﬂow of personal data” (1981) and “Guidelines for the
security of information systems” (1991/92), the ICare consortium in
particular acknowledges heterogeneity in international data protection
jurisdiction.
A three-armed multi-country RCT will be conducted to compare
guided and unguided IMIs with TAU. Trial sites are in Germany/
Switzerland, the Netherlands, and Spain. Both active conditions are
based on the same intervention ICare Prevent and diﬀer only with regard
to the guidance format (unguided and guided treatment). All inter-
vention arms will have full access to TAU. TAU diﬀers per country and
region. In all countries, TAU is likely to be heterogeneous but this is a
reﬂection of clinical practice. We will not interfere with nor manualize
TAU. However, to control for potential confounding eﬀects, TAU will be
closely monitored by self-report assessments. By this, we mean that
information on all types of medical help received during the duration of
the study will be collected so that an accurate description of TAU will
be available. After the initial screening, assessments will take place at
baseline (T1), mid-intervention (after completion of module 5 or
5 weeks after randomization, T2), post-intervention (8 weeks after
randomization, T3), at 6 months follow-up (T4), and at 12months
follow-up (T5). See Table 3 for a detailed overview of assessments. See
Fig. 1 for a detailed overview of the study design.
2.4. Intervention
The transdiagnostic individual tailored ICare Prevent online training
Fig. 1. Study Design.
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aims at reducing depressive complaints and anxieties, reduce associated
risk factors, and strengthen protective factors. The training is internet-
based and supported by a mobile app. Transdiagnostic elements of the
intervention include psychoeducation on etiological and maintaining
factors of depressive and anxiety symptoms, and targeting common risk
factors. Furthermore, the intervention can be individually tailored to
the speciﬁc need of the individual as participants can choose to focus on
problem solving, recommended for persons with depressive mood, or
practice exposition to fear-inducing situations, aimed at individuals
suﬀering from anxieties, and participants can continuously choose to
focus on topics of interest throughout the intervention. The transdiag-
nostic individual tailored approach enables to target both depression
and anxieties, but also to tailor the treatment to other individual pre-
ferences and risk factors. One main strategy of the intervention, com-
monly found in internet interventions, is the concept of self-help. To
foster self-help techniques, participants are encouraged to integrate and
practice newly acquired strategies in daily life through transfer tasks
(homework assignments). The intervention builds on adaptions of evi-
dence-based modules from an a range of previous interventions which
have shown to be eﬀective in the prevention of MDD (Buntrock et al.,
2016b; Ebert et al., 2016), treatment of depression (Buntrock et al.,
2015; Ebert et al., 2017a, 2017b; Ebert et al., 2016b; Nobis et al.,
2015), and sleeping problems (Ebert et al., 2015a, 2015b; Thiart et al.,
2015, 2016).
The intervention consists of eight modules: addressing needs (ses-
sion 1), behavioral activation (session 2), psychoeducation (session 3),
cognitive restructuring (session 4), problem solving or exposure (ses-
sion 5 and 6), planning for the future (session 7) and a booster session
(session 8) (see Table 1 for an overview of the main modules). Parti-
cipants can choose between two disorder-speciﬁc modules in session 5:
problem solving (training for participants who want to focus primarily
on the reduction of depressive symptoms) and exposure (for partici-
pants who want to focus on the reduction of symptoms of anxiety).
Another major element is that participants can choose between several
elective modules (integrated into sessions 2 to 7) based on individual
need and/or preference. The elective modules are directed at rumina-
tion & worries, acceptance, relaxation, alcohol & aﬀect regulation, self-
worth, perfectionism, appreciation and gratefulness, and sleep (see
Table 2 for an overview of the elective modules). Each session can be
completed in approximately 45 to 60min. We advise participants to do
at least one and a maximum of two sessions per week. Further content
can only be accessed once previous sessions are completed. Conse-
quently, the training lasts about 4 to 7 weeks plus one additional
booster session 4 weeks after completion of the last session. The booster
session aims to help participants transfer acquired strategies into daily
life. Sessions consist of texts, testimonials, audios, short educational
video clips, and also include interactive elements such as quizzes, ex-
ercises, and homework. Participants are also encouraged to keep an
online diary at certain intervals of the training which can be accessed
either via the web interface or an optional smartphone app. The in-
tervention uses content tailoring, thereby engaging the participant by
encouraging them to make real-time choices among various response
options, and then providing individualized content based on speciﬁc
needs or preference. The training is built on responsive web-design and
can be completed on any kind of internet-ready device, such as PCs/
laptops, smartphones, or tablets. Participants can follow narrated les-
sons by activating the read-aloud function. Participants can also opt to
receive motivational messages and small exercises referred to as Smart
Coach. These messages are sent directly to their mobile device. They
can choose between a light version (3 messages per day) and an in-
tensive version (5 messages per day). These notiﬁcations will support
the participants in transferring the exercises of the training into their
daily lives (e.g., short relaxation exercises: “Relax your muscles in your
hands and arms for 3 seconds now. Follow your breathing and each
time you breathe out, relax a little more.”).
2.4.1. Addressing needs (session 1)
In the ﬁrst session, participants receive an introduction to the
training and familiarize with the session content as well as the core
elements, such as testimonials, diaries, and videos. Motivation is
strengthened by assessing personal treatment motivation, and partici-
pants are asked to formulate realistic, individual and concrete goals
which can be modiﬁed and revised throughout the training. One main
focus of the intervention lies on reducing personal incongruence in
daily life, by supporting participants to achieve a balance between
personal needs and values, and behavior based on the congruence
theory by Grawe, 2004. Hence, participants are educated on the re-
lationship between personal needs and values, and psychological well-
being, and then work on identifying their unfulﬁlled needs and core
values. They are encouraged to plan activities which serve the purpose
of strengthening life areas important to them, and progress and diﬃ-
culties can be documented in the activity diary.
2.4.2. Behavioral activation (session 2)
In the second session, participants are presented with strategies on
how to deal with diﬃculties concerning the implementation of planned
activities and how to reduce avoidant behaviors. In addition to beha-
vioral activation strategies related to core personal needs and values
addressed in session one, they are also introduced to the concept of
mood stabilizing reinforcing activities that can be used to overcome
lowered mood, and participants are encouraged to plan exercising self-
chosen pleasant activities in their daily life.
2.4.3. Psychoeducation (session 3)
The participants are provided with psychoeducational information
on depression and anxiety, and the multifactorial causes explaining
etiology and maintenance. Participants are encouraged to identify
symptoms they have previously experienced or are currently dealing
with. Information on the diﬀerent forms of depression and anxiety in-
cluding diagnosis criteria is provided. To enhance the understanding of
the disorders, inﬂuencing factors beneﬁtting the development and
maintenance of depression and anxiety, risk factors, and the vicious
circles of upkeep are explained. After receiving general information,
participants can choose throughout the session whether to review de-
tailed information on one of the disorders (depression or anxiety) or
work through both. Participants are asked to identify their symptom
development and describe the course of their symptomology.
2.4.4. Cognitive restructuring (session 4)
In the fourth session, participants receive information on the causal
relationship between cognitions and emotions. Participants are in-
troduced to a thought record in which situations are divided into three
components: situations, thoughts, and consequences. Participants are
given the opportunity to individualize their personal thought records by
including personal situations, cognitions, and emotions. The im-
portance of negative emotions is also stated. In the second phase of the
thought record, participants are motivated to question the reality basis
of their negative thoughts, encouraged to ﬁnd positive and helpful
thoughts, and to generally concentrate on and practice positive thinking
Table 1
Content of the ICare Prevent training.
Intervention content Session
Addressing needs 1
Behavioral activation 2
Psychoeducation 3
Cognitive restructuring 4
Problem Solving or Exposure 5
Problem Solving or Exposure 6
Plan for the future 7
Booster session 8
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habits.
2.4.5. Problem solving or exposure (sessions 5 & 6)
Participants can choose whether they wish to work on 1) acquiring
and enhancing problem solving skills to reduce depressive sympto-
mology, or 2) practicing exposition to fear-inducing stimuli and situa-
tions to reduce feelings of anxiety.
Participants learn the distinction between solvable and unsolvable
problems and are asked to assign their own problems to these two ca-
tegories. They are introduced to the concept of a 6-step problem-solving
plan in which they: 1) identify a problem, 2) deﬁne a realistic target
state, 3) ﬁnd possible solutions and choose the seemingly best solution,
4) create a detailed solution plan, 5) practice a plan, and 6) verify the
implementation success. Participants are expected to practice their plan
during the following week in real life situations, and are encouraged to
analyze the success or failure of it in the following session. They can
also opt to review and adapt their plan in the following session.
Participants who wish to reduce anxieties are introduced to the
concept of avoidant and safety behavior, how confrontation of fear can
lead to habituation, and practice exposure to fear-inducing situations.
Participants are educated on the importance of confronting fears
through exposition, what actually happens during exposition, and why
it is more eﬀective in the long term perspective for enhancing well-
being than avoidance strategies. Participants are asked to identify
perceived diﬃcult and fear-inducing situations, and rate their expected
feelings of anxiety in relation to these situations. They are introduced to
strategies to deal with and work on overcoming their anxiety by ex-
posure to fear-provoking situations. It is recommended to start with less
threatening situations and once these seem manageable to work on
more severe situations. Participants are introduced to a challenge
management protocol, which intends to prepare them for the situations
they aim to work through. In the following session, they can evaluate
their implementation success, identify personal safety behavior, and
focus on facing more challenging situations. Participants are en-
couraged to create a plan for the upcoming weeks to practice exposition
to more fear-inducing situations.
2.4.6. Plan for the future (session 7)
In the last training session, participants can review brief summaries
of each session. They are asked to reﬂect on progress concerning their
training goals, and to identify mechanisms of the training that helped
them. They are also given the opportunity to write a letter to their
future selves assuming they have completed four more weeks of prac-
tice of acquired strategies. Subsequently they are encouraged to make a
plan of speciﬁc strategies they want to continue to train in everyday life
until the booster session, in order to maintain and generalize acquired
strategies.
2.4.7. Booster session (session 8)
The participants are invited to complete a booster session four
weeks after completion of the seventh session. In this session, they can
reﬂect on their learning experience and personal goal attainment. They
are asked to reﬂect on their current state of mental health, and provided
with additional information on support, if needed. Participants can
review the letter they wrote to themselves in the last training session,
can reformulate their goals and are asked to make plans to implement
their intentions in the coming months.
2.4.8. Support
2.4.8.1. Guided treatment. During the active intervention phase
participants of the guided treatment arm are supported by an eCoach
who provides individual manualized feedback after completion of each
session. eCoaches will have at least a Bachelor's degree in Psychology
and have access to supervision when required. Guidance is manualized,
eCoaches use preformulated standardized text blocks that are prepared
for every lesson. The standardized text blocks are individually adapted
to the clients input and overall progress. The eCoaches communicate
with participants through the internal messaging function of the
platform. Estimated mean time per feedback is 20min. eCoaches are
advised not use> 30min per individual feedback. Approximately 2.5 h
is the total time an eCoach will spend per participant. Session
adherence is also monitored, when participants fail to complete a
session within 7 days, eCoaches will send out email reminders (after 7,
14, and 21 days). Additionally, after 28 days a reminder will be sent via
text message (not in the Netherlands NL). Both personal and automatic
reminders have shown to improve adherence to self-guided health
promotion and behavior change interventions (Fry and Neﬀ, 2009;
Titov et al., 2013).
2.4.8.2. Unguided treatment. Participants of the unguided treatment
arm do not receive any individualized feedback, however, after
completion of a session, they will receive encouraging standardized
messages automatically sent through the training platform. Session
adherence is monitored and participants are also provided with
messages based on non-adherence. Should participants fail to
complete a session within 7 days, they will receive standardized email
reminders (after 7, 14, 21 days) by the study administration team
encouraging them to continue working on the current module. If
participants fail to respond within 28 days, they will receive a
reminder via text message (not in NL).
All study participants can contact a support email address
(support@icareprevent.com) in case of any technical diﬃculties with
the training or the assessments.
2.5. Assessment and data management
Data management and monitoring will be provided by the Institute
of Biostatistics and Clinical Research (Westfälische Wilhelms-
Universität Münster) for the whole ICare consortium in order to
maintain comparable high quality in the conduct of the ICare research
projects in trial planning, data management, online monitoring, and
analysis.
Self-reports and observer-based assessments will take place at
screening (T0), baseline (T1), mid-intervention (T2, after completion of
module 5 or 5 weeks after randomization), post-intervention (T3,
8 weeks after randomization), and at 6- (T4) and 12-month follow-ups
(T5). Observer-based assessments from clinical diagnostic interviews
will be carried out via telephone. Self-report data will be collected using
a secured online-based assessment system (AES, 256-bit encrypted).
2.5.1. Observer-based assessments
Diagnostic clinical interviews will be conducted at baseline, at post-
intervention, and at 6- and 12-month follow-up. The interviews consist
of an adaption of the MINI focusing on depression and any anxiety
disorder (Mini 5.0) (Sheehan et al., 2006), the Quick Item Inventory of
Depressive Symptomatology clinician rating (QIDS-C) (Rush et al.,
2003), and structured interview of the Hamilton Anxiety Rating Scale
Table 2
Content of the ICare Prevent elective modules.
Rumination & worries: Dealing with excessive worrying & reducing
rumination habits
Acceptance: Acceptance of undesired aﬀective states
Relaxation: Progressive muscle relaxation
Alcohol & aﬀect regulation: Reducing aﬀect regulation related alcohol
consumption
Self-worth: Acknowledging and strengthening self-worth
Perfectionism: Dealing with perfectionism
Appreciation &
gratefulness:
Practicing mindfulness strategies
Sleep: Improving sleep hygiene and practicing sleep
restriction to enhance sleep quality
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(SIGH-A) (Hamilton, 1959; Shear et al., 2001). The MINI will not be
assessed at post-intervention.
All clinical interviews will be conducted by trained master psy-
chology students or experienced psychotherapists who are blind to
treatment condition. The interviews will be recorded and approxi-
mately 10% of the cases will be assessed by another rater to examine
interrater reliability. Disagreement shall be solved by discussion and
the agreed rating will be used for analysis. If this is not possible, the
assessment will be rated by an experienced psychotherapist (gold
standard) and this rating will be used for analysis. Interrater reliability
will be reported for each trial site (Germany/Switzerland, Spain and the
Netherlands) individually. Measures to assure blinding include: (a)
explanation to the participant the importance of keeping the assessors
blinded to randomization status; (b) verbal reminder to the participant
before each assessment; and (c) documentation after each assessment,
whether the interviewer is still blind to treatment condition. In case of
evidence for blinding break down, the interviewer will be changed to
the next outcome interview. The interviewers will be asked to guess
each participant's randomization status. These guesses will be com-
pared with the actual status. Cohen's kappa will be computed to clarify
whether hit rates diﬀer from what can be expected from chance.
2.6. Outcomes
2.6.1. Primary outcome
Primary outcome will be time to CMD onset (any anxiety/depres-
sion disorder) in guided and unguided IMI compared to TAU within a
12months follow-up period assessed by the MINI 5.0 (Sheehan et al.,
2006). The Mini will be assessed at baseline, 6 months follow-up (FU)
and 12months FU. The frequency of outcome interviews allows for a
temporal precision of onset of CMD within the inspected timeframe.
The exact time to CMD onset (given in weeks since randomization) will
be assessed as accurately as possible using the Life Chart method de-
veloped by Lyketsos et al. (1994) in order to reduce a potential recall
bias. In this method, age- and calendar-linked personal landmarks are
used to assess the time sequence of i.e. depressive symptomatology and
life events in parallel. During the interview the ﬁrst day of an episode
will be established. If the exact day could not be established, the closest
week (month) will be deﬁned and the mid-point of that week (month)
will be used.
2.6.2. Secondary outcomes
2.6.2.1. Observer-based. Observer-rated depressive symptom severity is
assessed by clinician ratings by the QIDS-C (Rush et al., 2003) at
baseline, 8 weeks post-intervention, at 6- and 12-month follow-up. It
encompasses the following nine criteria in 16 items: sleep, sad mood,
appetite/weight, concentration/decision making, self-view, thoughts of
death or suicide, general interest, energy level, and restlessness/
agitation. Each item is answered on a scale from 0 to 3, and total
scores range from 0 to 27 (Rush et al., 2003). A meta-analysis showed
Cronbach's alpha (α) was found to be acceptable (α=0.69–0.89)
(Reilly et al., 2015).
Observer rated anxiety symptom severity will be assessed using the
SIGH-A (Shear et al., 2001) at baseline, 8 weeks post-intervention, at 6-
and 12-month follow-up to assess the severity of anxiety. It consists of
14 items rated from 0 to 4, 4 being the most severe. The score is
summed to receive an overall rating of anxiety severity ranging from 0
to 56. Test-retest reliability of the SIGH-A was 0.89 (Shear et al., 2001).
2.6.2.2. Self-report. The complete list of self-report measures and
measurement time points are shown in Table 3.
2.6.2.3. Psychopathology. Self-reported depressive symptoms will be
measured with the Center for Epidemiological Studies Depression
Scale (CES-D) (Radloﬀ, 1977). This frequently used self-report
instrument consists of 20 items that are answered on a four-point
Table 3
Overview study self-report assessments.
Construct Questionnaire T0 T1 T2 T3 T4 T5
Demographics Socio-demographic data
(SozDemo)
✔ – – – – –
Psychopathology
Mental health
Mental health (PG) ✔ – – – – –
Psychopathology
Depression
Center for Epidemiological
Studies Depression Scale -
Short Version (CES-D)⁎
✔ – ✔ ✔ ✔ ✔
Psychopathology
Anxiety
General Anxiety Disorder
Measurement (GAD-7)
✔ – ✔ ✔ ✔ ✔
Psychopathology
Depression
Patient Health
Questionnaire (PHQ-9)
– ✔ ✔ ✔ ✔ ✔
Psychopathology
Alcohol abuse
The Alcohol Use Disorders
Identiﬁcation Test (AUDIT-
C)
– ✔ ✔ ✔ ✔ ✔
Quality of life
Wellbeing
WHO-Five Wellbeing Index
(WHO-5)
– ✔ – ✔ ✔ ✔
Quality of life EuroQol (EQ-5D) – ✔ – ✔ ✔ ✔
Quality of life Assessment Quality of Life
(AQoL-8D)
– ✔ – ✔ ✔ ✔
Quality of life
Health economic
evaluation
Client Service Receipt
Inventory (CSRI)
– ✔ – – ✔ ✔
Training
Expectancy
Credibility/Expectancy
Questionnaire (CEQ)
– ✔ – – – –
Training
Negative treatment
eﬀects
Inventory to assess
negative eﬀects of
psychotherapy (INEP)
– – – ✔ – –
Training
Program
evaluation
(Based on) Client
Satisfaction Questionnaire
(CSQ-8)
– – ✔ ✔ – –
Training
Attitudes toward
help
Attitudes Toward Seeking
Professional Help
(ATSPPHS)⁎
– ✔ – ✔ – –
Training
Supportive
accountability
Supporting Accountability
(SA)
– – ✔ – – –
Training
Treatment
Satisfaction
(adaption of) Working
Alliance Inventory SR
(WAI-SR)
– – ✔ – – –
Risk factors
Risk factors
questionnaire
Risk Factor Questionnaire
(developed by ICare
Prevent team) (RF)
– ✔ – – – –
Risk factor
Worry
Penn State Worry
Questionnaire – Ultra Brief
(PSWQ-3)
– ✔ – ✔ ✔ ✔
Risk factor
Sleep
Pittsburgh Sleep Quality
Index (PSQI)
– ✔ – ✔ ✔ ✔
Risk factor
Self-esteem
Rosenberg Self Esteem
Scale (RSES)
– ✔ ✔ – – –
Risk factor
Resilience
Connor-Davidson
Resilience Scale (CD-RISC)
– ✔ ✔ ✔ ✔ ✔
Other
Emotion regulation
Subscales of emotion
regulation scale
questionnaire (SEK-15)
– ✔ – ✔ ✔ ✔
Other
Incongruence
Incongruence
questionnaire (short
version) (INK-K)
– ✔ ✔ ✔ ✔ ✔
Other
Personality
Big Five Inventory (BFI-10) – ✔ – – – –
Other
Self-regulation
Self-Regulation Scale
(SSRQ)⁎
– ✔ – – – –
Other
Behavioral
activation
The Behavioral Activation
for Depression Scale
(BADS-FS-9)
– ✔ – ✔ ✔ ✔
Other Drop-Out Reasons
(developed by ICare
Prevent team) (DG)
– – – ✔ – –
(continued on next page)
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Likert scale referring to the previous week. Total scores range from 0 to
60. The internal consistency of this measure has been found to be
excellent (α=0.95) (Lehr et al., 2008). Depressive symptoms are also
measured by the Patient Health Questionnaire (PHQ-9) (Kroenke et al.,
2001) and consist of 9 items. Each item covers one of the nine DSM-IV
criteria for the diagnosis of a major depression. This instrument has a
high internal reliability (α=0.89) and also test-retest reliability with
0.84 (Löwe et al., 2004; Martin et al., 2006; Spitzer et al., 2006), and
shown to have a good interformat reliability to paper, when delivered
online (Erbe et al., 2016).
The generalized anxiety disorder measurement (GAD-7) (Spitzer
et al., 2006) is used to assess GAD and symptom severity. It consists of 7
items answered from 0 (not at all) to 3 (nearly every day). It possesses
excellent internal consistency (α=0.92) and good test-retest reliability
(intraclass correlation (ICC)= 0.83) (Löwe et al., 2008; Spitzer et al.,
2006).
Substance abuse will be assessed by a 3 item alcohol screen (AUDIT-
C) (Bush et al., 1998). Each item is answered on a 5-point Likert scale
and the total score ranges from 0 to 12. This measurement has accep-
table psychometric properties (α=0.61, ICC=0.89) (Bradley et al.,
2007; Dybek, 2008).
Worry will be assessed by the 3 item Penn State worry questionnaire
ultra brief (PSWQ-3; range 0–18, α=0.85) (Berle et al., 2011; Meyer
et al., 1990)
Sleep quality will be assessed by the 1 item subscale of the
Pittsburgh sleep quality index (PSQI) (Buysse et al., 1989), answered on
a 4-point Likert scale. Psychometric properties are acceptable
(α=0.74, ICC= 0.86) (Mondal et al., 2013; Rener-Sitar et al., 2014)
2.6.2.4. Quality of life. To measure quality of life we will use the
Assessment of Quality of Life Instrument (AQoL-8D) (Richardson et al.,
2014; Richardson and Rothstein, 2008), which consists of 35 items.
They entail eight dimensions: independent living (α=0.9,
ICC=0.86), pain (α=0.85, ICC=0.86), senses (α=0.69,
ICC=0.51), mental health (α=0.84, ICC= 0.89), happiness
(α=0.85, ICC= 0.90), coping (α=0.80, ICC=0.79), relationships
(α=0.73, ICC= 0.88), self-worth (α=0.85, ICC=0.81) (Richardson
et al., 2014). Psychometrics properties are, therefore, acceptable.
Additionally, the EuroQol (Group, 1990), consisting of ﬁve dimen-
sions (EQ-5D-5 L) and a visual analogue scale for self-rated health state,
will be applied to measure health-related quality of life. The dimensions
consist of mobility, self-care, usual activities, pain/discomfort and are
answered on a 5-point scale from 1 (no problems) to 5 (severe pro-
blems). Psychometric properties are acceptable (α=0.7, ICC=0.64)
(King et al., 2009; Luo et al., 2003).
The AQoL-8D and EQ-5D-5 L ratings will be used in the economic
evaluation.
2.6.2.5. Well-being. Well-being will be assessed by the 5-item WHO-5
Well-Being Index (WHO-5) (World Health Organisation, 1998)
answered on a 0 through 5 scale, and scores range from 0 to 30
(α=0.82) (de Wit et al., 2007).
2.6.3. Health economic evaluation
Key to the cost-eﬀectiveness and cost-utility analyses is information
on the impact of the intervention on publicly funded services and the
wider society. Individuals' use of services and supports will be recorded
on an adapted client service receipt inventory (CSRI) (Beecham and
Knapp, 2001) alongside wider societal impacts such as productivity
loss. Unit costs will be estimated for each service and support used
following well-established theory-driven methods and multiplied by the
use made be each individual to obtain a cost per person (Beecham,
2000). Costs will be expressed in the same currency across countries
using OECD purchasing power parities data
2.6.4. Training and acceptability
User satisfaction will be assessed by a questionnaire based on the
Client Satisfaction Questionnaire (CSQ-8) (Attkisson and Zwick, 1982),
adapted to assess user satisfaction in online interventions (Boß et al.,
2016). Global client satisfaction with internet-based training is mea-
sured by 8 items. Previous research indicated good psychometric
properties (α=0.84–0.97) (Matsubara et al., 2013).
Other measures related to the training include participant ex-
pectation (CEQ) (Borkovec and Nau, 1972; Devilly and Borkovec,
2000), satisfaction with treatment, an adaption of the Working Alliance
Inventory (WAI) (Horvath and Greenberg, 1989), negative eﬀects of the
treatment (INEP) (Ladwig et al., 2014), and attitudes toward seeking
professional psychological help (ATSPPH) (Fischer and Farina, 1995;
Surgenor, 1985). Lastly, the occurrence of any negative eﬀects will be
identiﬁed as in Rozental et al. at the 12months follow-up (Rozental
et al., 2015).
2.6.5. Response
To determine the numbers of participants achieving a reliable po-
sitive outcome, we will code participants as responders or non-re-
sponders according to the widely used reliable change index (RCI)
(Jacobson and Truax, 1991) after participation in the intervention.
Participants will be considered responders when they display an RCI
score of above 1.96.
2.6.6. Other assessments
Other assessments include demographics (e.g., age, gender, occu-
pation, level of education etc.), current and previous mental health is-
sues, current and previous experience with psychotherapy, personality
dimensions measured by the ultra-short version of the Big Five
Inventory (BFI-10) (Rammstedt and John, 2007), behavioral activation
(BADS-FS) (Fuhr et al., 2016; Kanter et al., 2012; Martell et al., 2001),
self-regulation (SSRQ) (Carey et al., 2004), self-esteem (RSES)
(Rosenberg, 1965), resilience (CD-RISC) (Connor and Davidson, 2003),
motivation (TEQ) (Ryan et al., 1995), various emotion regulation skills
(subscales comprehension, acceptance, and emotional self-support by
the German Emotion Regulation Scale Questionnaire, ERSQ-27, ERSQ-
ES-GD) (Berking and Znoj, 2008; Ebert et al., 2013).
Additionally, risk factors for the onset of depression and anxiety,
e.g. aspects of physical health, traumatic childhood and life events,
family psychopathology, social environment, are assessed at baseline in
order to investigate moderators of treatment outcome.
Adherence will be tracked by the system based on session comple-
tion.
2.6.7. Qualitative interviews
At least 10 participants with predominantly subclinical depression
and anxiety symptoms that have been randomized to the intervention
condition who have completed the intervention or who dropped out,
will be asked to participate in qualitative interviews. The qualitative
interviews aim at collecting subjective information on factors regarding
training eﬃcacy and adherence. These type of interviews can help
improve IMIs with the goal of heightening engagement. Aspects as-
sessed by the interview will include a) participants hope of
Table 3 (continued)
Construct Questionnaire T0 T1 T2 T3 T4 T5
Other Other help (developed by
ICare Prevent team) (INH)
– – – ✔ – –
T0= screening, T1= baseline, T2= 5weeks after randomization, T3=post-
intervention, 8 weeks after randomization, T4= 6-month follow-up, T5= 12-
month follow-up.
⁎ Trial site Netherlands will assess the CES-D only at screening and will not
assess ATSPPHS, SSRQ and SEK, participation will be optional in the risk factor
questionnaire.
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improvement and expectations, b) perceived usefulness of the training,
c) reasons for treatment success and failure, d) reasons for training
adherence and non-adherence, e) usability and layout, f) quality and
content of the intervention and received guidance, and g) overall
strengths and limitations of the training. The analysis of the interviews
is based on the qualitative content analysis by Mayring and Kuckarts
(Kuckartz et al., 2009; Mayring, 2010).
2.7. Statistical methods
Data will be analyzed on an intention-to-treat basis including all
participants who will be randomly assigned to conditions. Additionally,
a per protocol analysis (PPA) will be conducted including only parti-
cipants satisfying treatment protocol and assessments.
Time to onset of CMD between unguided and guided ICare Prevent
and TAU will be analyzed by a two-sided log rank tests. We will test the
two primary statistical hypotheses, i.e. (i) guided training vs. TAU and
(ii) unguided training vs. TAU. The emerging multiple testing problem
will be considered appropriately, by using a Bonferroni adjustment of
local signiﬁcance levels. Comparing survival curves instead of just onset
rates allows a more precise estimation of the intervention eﬀects and
also increases power, thereby allowing for the detection of smaller ef-
fects. Missing data will be handled by censoring.
For diﬀerences in the change of depression and anxiety symptom
severity multi-level mixed models regression analyses will be used.
Depending on the distribution of data in the various outcome para-
meters we will choose either linear models (for normally distributed
data) or negative binomial models (for left-skewed data). Each model
includes assessment time as a predictor. The inﬂuence of potential
predictive factors will be investigated by adding corresponding inter-
action terms to the model. All analysis will ﬁrst be adjusted for country,
type of subclinical symptoms, baseline symptom severity, history of
mental health disorder, previous treatment experience and potential
comorbid disorders. Missing data will be handled using multiple im-
putation.
We will also conduct a number of pre-planned exploratory subgroup
analyses such as a) per country, b) per disorder, c) with/without co-
morbidity (depression & any anxiety; depression & alcohol abuse; any
anxiety & alcohol abuse; combination of diﬀerent speciﬁc anxiety dis-
order symptoms anxiety comorbidities). d) Moreover, we will create a
multivariate risk prediction algorithm based on baseline risk factors and
in which we will test the assumption that individuals with high vs. low
predicted risk show a diﬀerential treatment eﬀect.
For all analyses on continuous measures, Cohen's d (Cohen, 1977)
will be calculated by standardizing the diﬀerences between baseline
and follow-up scores by the pooled standard deviation of the baselines
scores. The response rates will be compared across conditions with the
help of contingency tables and Chi-Squared tests. The global sig-
niﬁcance level of the two null hypotheses tested within the primary
analysis of the trial will be maintained by Bonferroni correction. Thus,
the local signiﬁcance levels are 2.5%. For the explorative analysis of the
data, the signiﬁcance levels will be set to 5%. Thus, p≤ 0.05 will in-
dicate the rejection of the respective null-hypothesis. The number
needed-to-treat (NNT) with ICare Prevent (guided and unguided) to
prevent one case of a CMD, respectively to achieve one response as
compared to the control group, will be calculated.
The health-economic evaluation will involve a combination of a
cost-eﬀectiveness analysis (CEA) and a cost-utility analysis (CUA). The
economic evaluation will be performed from a societal perspective (all
relevant costs) and public sector costs with a time horizon of 12months.
In the CEA, the incremental cost-eﬀectiveness ratio (ICER) will be ex-
pressed as the incremental costs per additional disorder free partici-
pant. In the CUA, the ICER will be expressed as incremental costs per
quality-adjusted life year gained (QALY) as based on the EQ-5D-5 L.
Bootstrapping (5000 times) will be used to quantify the uncertainty
around the ICER. The bootstrapped ICERs will be plotted on a cost-
eﬀectiveness plane where the horizontal axis reﬂects diﬀerences in ef-
fects and the vertical axis diﬀerences in costs. The bootstrapped ICERs
will also be shown in a cost-eﬀective acceptability curve disclosing the
probability that the intervention is cost-eﬀective for a range of will-
ingness-to-pay ceilings. To test the robustness of the base-case ﬁndings,
a multi-way sensitivity analysis will be conducted. Several assumptions
made in the base-case scenario (eg. QALYs based EQ-5D instead of the
AQoL-8D) will be changed to assess their impact on the ICER.
The statistical analysis of the primary and secondary outcomes will
be described in a statistical analysis plan that will be signed by the
study committee and the responsible statistician.
2.8. Sample size calculation
In primary analysis we aim to explore the eﬀects of the intervention
on time to disorder onset. Based on meta-analytic evidence on the
prevention of depression (van Zoonen et al., 2014) and randomized
trials on combined prevention of depression and anxiety (van't Veer-
Tazelaar et al., 2009b), we expect a mean 12-month survival rate (i.e.,
no disorder onset) in the control group of 75% (25% incidence rate),
and 85% (15% incidence rate) in the active conditions, which translate
in an absolute risk reduction of 10% and a relative risk reduction of
40%. This is a more conservative estimation than 50% relative risk
reduction found in the only trial that has to the best of our knowledge
been conducted on the combined indicated prevention of depression
and anxiety. To detect such a diﬀerence between the active conditions
and the control condition with a power of 80% and a signiﬁcance level
of 0.05, 254 participants are needed per group (762 in total). Ac-
counting for 20% drop-out, 954 participants in total need to be re-
cruited (n=363 per group).
Based on the mean results from studies evaluating interventions
aimed at the indicated prevention of a CMD (Allart-Van Dam et al.,
2003; Clarke et al., 1995; de Jonge et al., 2009; Sheﬃeld et al., 2006;
van't Veer-Tazelaar et al., 2009b; Willemse et al., 2004) we expect an
eﬀect of d= 0.35 (Cuijpers et al., 2014a); diﬀerence in the reduction in
secondary outcome depression severity between the active groups and
the control group. So far evidence for internet-based interventions for
subclinical symptoms of anxiety is lacking. Meta analytic evidence for
internet interventions targeting anxiety disorders indicates an eﬀect of
d= 0.90 for internet-based guided self-help treatments and d= 0.58
for interventions without guidance. Given that the present trial targets
individuals with subclinical symptoms with less room for improvement,
much lower eﬀects can be expected. Hence, we expect an eﬀect size of
d= 0.30.
3. Discussion
Depression and anxiety disorders are greatly prevalent globally and
highly comorbid, associated with a decline of quality of life, and linked
to substantial economic costs. IMIs could be an attractive, eﬃcient and
cost-eﬀective approach to prevent the development of CMDs, by redu-
cing the onset probability of full syndrome CMDs, and targeted at at-
risk population transdiagnostic IMIs could help reduce overall disease
burden.
To date, few RCTs have been conducted on the prevention of CMDs,
and data for transdiagnostic treatment protocols are scarce. A re-
maining open research question is whether guided or unguided inter-
ventions are more cost-eﬀective when implemented on a large scale.
After the development of internet-based interventions, the most pro-
minent cost factor is substantially linked to guidance time, and this
relationship has not yet been examined in the context of interventions
aimed to prevent the incidence of CMDs.
Overall, the present study will be the ﬁrst to provide evidence for
the eﬃcacy and cost-eﬀectiveness of transdiagnostic preventive inter-
ventions and provide valuable information on the optimal trade-oﬀ
between treatment outcome and economical costs.
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The present study has several strengths, including the strong
methodology of a randomized controlled design with the direct com-
parison of two active conditions. The assessments include diagnostic
outcome interviews as an objective addition to the self-report mea-
surements. Also, there is an appropriate statistical analyses plan and
missing data will be handled with state of the art methods. The treat-
ment protocol is transdiagnostic and individual tailored adding to
empirical evidence of treatment options targeting a heterogeneous at-
risk group. Lastly, the online training is technically advanced as it relies
upon content tailoring which allows the participant to make real-time
choices which trigger diﬀerent content based on preference or need.
This study also has some limitations. First, as the study is powered
to detect diﬀerences between the active groups compared to the TAU
group in the primary outcome onset of CMDs, the sample size will be
insuﬃcient to draw reliable conclusions on the diﬀerential eﬀectiveness
of guided vs. unguided IMIs regarding disorder onset. It will remain
unclear which participants are likely not to proﬁt from unguided
treatment but would potentially proﬁt from guided IMIs. Second, al-
though pooling data from the four participating countries increases the
feasibility of reaching the necessary sample size, diﬀerences between
participants of the diﬀerent trial sites need to be considered when in-
terpreting the results which could contain larger variance than if con-
ducted solely in one trial site. However, as the study is embedded in the
ICare consortium whose goal it is to implement, to disseminate, and to
increase acceptability of internet-based mental health interventions
across Europe, it is a necessary risk and will also provide valuable in-
formation on the overall eﬀectiveness of IMIs for the prevention of CMD
in heterogeneous settings in Europe. Third, assessments take place only
at post-intervention and follow-up time points; there will be no am-
bulatory assessment. Therefore, the results will have to be interpreted
in relation to these predeﬁned time points. As the intervention is time-
consuming in itself and the assessments can be tedious, it was decided
not to burden participants any further and possibly risk drop-out with
weekly or even daily assessments, and the diagnostic interviews allow
for temporal precision determining onset. And lastly, the study has an
elaborate screening process. This poses the risk that highly motivated
individuals will be more likely to participate in the intervention. In
future, interventions must be implemented with low threshold access,
in order to estimate the eﬀects when delivered under routine care
conditions.
4. Conclusion
To overcome the gap between the need for economical eﬀective
strategies for preventing mental health disorders and evidence-based
treatment availability, (cost-)eﬀective, low-threshold interventions,
accessible to as many people as possible, are needed. Internet- and
mobile-based mental health interventions are a promising strategy to
overcome some of the limitations of face-to-face mental health inter-
ventions. This study will enhance the evidence-base for IMIs and pro-
vide information on the diﬀerential eﬃcacy, and cost-eﬀectiveness of
two guidance forms of ICare Prevent.
Trial status
The ﬁrst participants were enrolled in the study on February 1, 2017
Follow-up assessments for the remaining patients are expected to be
completed by September 1, 2019.
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